Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft.
Bestard
Oriol
O
Department of Nephrology, Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. 35830obm@comb.es
Cruzado
Josep M
JM
Ercilla
Guadalupe
G
Gomà
Montse
M
Torras
Joan
J
Serón
Daniel
D
Rama
Inés
I
Ibernon
Meritxell
M
Viñas
Odette
O
Carrera
Marta
M
Grinyó
Josep M
JM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D016175:B-Lymphocyte Subsets / Q000187:drug effects; D002196:Capillaries / Q000737:chemistry; D015935:Complement C4b / Q000032:analysis; D000075202:Contraindications; D003449:Cryoglobulinemia / Q000188:drug therapy / Q000209:etiology; D005234:Fatty Liver / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery / Q000628:therapy; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016898:Interferon-alpha; D016030:Kidney Transplantation; D018655:Lymphocyte Count; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D011183:Postoperative Complications / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012008:Recurrence; D006435:Renal Dialysis; D012086:Reoperation; D000069283:Rituximab; D014184:Transplantation, Homologous; D019562:Viral Load; D014766:Viremia / Q000150:complications* / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D010446:Peptide Fragments; D000069283:Rituximab; D015935:Complement C4b; C032261:complement C4d